Organogenesis (NASDAQ:ORGO – Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a report issued on Sunday, Wall Street Zen reports.
A number of other brokerages have also recently issued reports on ORGO. Truist Financial cut their target price on Organogenesis from $3.00 to $2.00 and set a “hold” rating on the stock in a report on Friday, August 7th. Weiss Ratings upgraded shares of Organogenesis from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, November 9th. Two investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Reduce” and an average target price of $4.33.
View Our Latest Research Report on ORGO
Organogenesis Price Performance
ORGO stock opened at $0.80 on Friday. The stock’s 50 day simple moving average is $1.17 and its 200 day simple moving average is $2.22. The company has a quick ratio of 2.76, a current ratio of 3.32 and a debt-to-equity ratio of 0.09. Organogenesis has a fifty-two week low of $0.73 and a fifty-two week high of $6.20.
Organogenesis (NASDAQ:ORGO – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). The firm had revenue of $45.46 million during the quarter, compared to analyst estimates of $52.10 million. Organogenesis had a negative net margin of 39.34% and a negative return on equity of 55.28%.
Hedge Funds Weigh In On Organogenesis
Large investors have recently added to or reduced their stakes in the business. Waverly Advisors LLC acquired a new position in Organogenesis during the 2nd quarter valued at about $25,000. Sequoia Financial Advisors LLC purchased a new stake in shares of Organogenesis in the second quarter worth approximately $33,000. Pallas Capital Advisors LLC purchased a new stake in shares of Organogenesis in the second quarter worth approximately $37,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Organogenesis in the second quarter worth approximately $44,000. Finally, Capital Square LLC bought a new position in shares of Organogenesis in the second quarter valued at approximately $45,000. Institutional investors own 49.57% of the company’s stock.
Organogenesis Company Profile
Organogenesis Holdings Inc. is a regenerative medicine company that develops, manufactures and commercializes products for advanced wound care and surgical and sports medicine. The company’s products are designed to support tissue repair and healing in a range of clinical settings. Its portfolio includes wound-care products such as Apligraf, a bioengineered skin substitute, and products made from or incorporating materials including placental tissue and purified collagen. Organogenesis also offers products for surgical and sports medicine applications.
Further Reading
- Five stocks we like better than Organogenesis
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.
